Clinical trials: Covid19 Vaccine
SARS-CoV-2 Infection, Covid19
Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers
With the unprecedented morbidity of the COVID-19 pandemic, the vaccine effectiveness needs to be assessed across diverse populations.
- Trial name
- NCT04795414
- Testing
- SARS-CoV-2 Vaccine(Vero Cell), Inactivated
- Where
- China
- Volunteers
- 1,370 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Covid19
A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19
To investigate the safety and immunogenicity profile of of a novel and investigational SARS-CoV-2 DNA vaccine, which is delivered intramuscularly followed by electroporation to enhance vaccine penetration, as a potential…
- Trial name
- NCT05102643
- Testing
- SARS-CoV-2 DNA Vaccine
- Where
- Hong Kong
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Covid-19, Protection Against COVID-19
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was skipped due to changes in the overall clinical development plan.
- Trial name
- NCT04537949
- Testing
- BNT162b3
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, Sars-CoV-2 Infection
Phase 3 Booster Vaccination Against COVID-19
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac…
- Trial name
- NCT05077176
- Testing
- CoronaVac, Turkovac
- Where
- 41 sites in Turkey (Türkiye)
- Volunteers
- 4,340 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Rheumatic Diseases
COVID-19 Vaccination in Patients With Rheumatic Diseases
The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.
- Trial name
- SAR-CoVAC (NCT04845997)
- Testing
- COVID-19 Vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 3,000 people
- Sponsor
- Sociedad Argentina de Reumatologia
COVID-19
Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents
This study is a global multi-center , case-driven, randomized, double-blinded, and placebo-controlled phase Ⅲ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04992260
- Testing
- Inactivated COVID-19 Vaccine, Controlled vaccine
- Where
- 38 sites in Chile, Malaysia and 2 more
- Volunteers
- 11,349 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes
This is an open-label, randomized, parallel-controlled clinical trial conducted in people aged 18 years and older to evaluate the immunogenicity and safety of two SARS-CoV-2 bivalent vaccines constructed by adenovirus type…
- Trial name
- NCT05886790
- Testing
- Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation, Bivalent COVID-19 mRNA Vaccine, Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.
- Trial name
- NCT04522089
- Testing
- AdimrSC-2f
- Where
- Taiwan
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
COVID-19
Dose-finding Study for AdimrSC-2f Vaccine
AdimrSC-2f is a subunit protein-based vaccine produced using the baculovirus insect cells manufacturing process to prevent Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT05104489
- Testing
- AdimrSC-2f
- Where
- Indonesia
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Covid19, Vaccines
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults
The study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults.
- Trial name
- CoronaVac3CL (NCT04651790)
- Testing
- SARS-CoV-2 inactivated vaccine
- Where
- Chile
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Wellness, Burnout, Caregiver
Evaluating the Impact of Resource Navigators to Support LTC and RH Staff During and Beyond COVID-19
The goal of this clinical trial is to test how well resource navigators help long-term care and retirement home staff access the various health and wellness resources available to them and the effects that this has on their…
- Conditions
- Wellness, Burnout, Caregiver, Burnout, Professional, COVID-19
- Trial name
- NCT05677997
- Testing
- Intervention
- Where
- Canada
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
SARS-CoV-2
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid.
- Trial name
- CORVax12 (NCT04627675)
- Testing
- CORVax, IL-12 plasmid, Cliniporator
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Providence Health & Services
Vaccination, COVID-19
COVID-19 Vaccine Messaging, Part 1
This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm.
- Trial name
- NCT04460703
- Testing
- Control message, Baseline message, Personal freedom message
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Adverse Reaction to Vaccine, COVID19 Vaccine
COVID-19 Vaccines Safety Tracking (CoVaST)
This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine…
- Trial name
- NCT04834869
- Testing
- BNT162b2, mRNA-1273, AZD1222
- Where
- 14 sites in United States, Canada and 12 more
- Volunteers
- 30,000 people
- Sponsor
- Masaryk University
Liver Disease Chronic
COVID-19 Vaccines in Patients With Chronic Liver Disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020.Patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19.
- Trial name
- NCT05017805
- Testing
- COVID-19 Vaccines
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing 302 Hospital
COVID-19 Prevention
An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine
Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers.
- Trial name
- NCT04713488
- Testing
- Sputnik Light
- Where
- Russia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels
To determine if patients with a history of Diabetes Mellitus Type I or II developed a change in blood glucose levels as reported on Continuous glucose monitoring devices (CGMS) within the first week following administration of…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
- Trial name
- NCT04923386
- Testing
- None (not interventional)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Levenson, David I., M.D.
Corona Virus Infection, Vaccine
An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) Produced by FSBSI "Chumakov…
- Conditions
- Corona Virus Infection, Vaccine, COVID-19
- Trial name
- NCT05765773
- Testing
- CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI "Chumakov FSC R&D IBP RAS"
- Where
- 7 sites in Russia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
COVID-19 Prevention
Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same…
- Trial name
- SPUTNIK-LIGHT (NCT04741061)
- Testing
- Sputnik Light
- Where
- 15 sites in Russia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
COVID-19
Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine
RT-CoV-2 is a Phase I, open-label, dose escalation multicenter clinical trial to assess safety and immunogenicity of the candidate Coronavirus disease (COVID-19) vaccine GRAd-COV2 in Italian healthy volunteers aged 18-55 years…
- Trial name
- NCT04528641
- Testing
- GRAd-COV2
- Where
- 2 sites in Italy
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- ReiThera Srl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.